XtalPi Holdings (HKEX: 02228) has announced a partnership worth over USD 400 million with an undisclosed international biopharma company to develop oral small molecule therapeutics against a GPCR target in metabolic disease — the largest single-program deal disclosed by the China-based AI drug discovery platform to date. The collaboration builds on a completed pilot phase in which XtalPi's quantum physics and AI platform demonstrated hit rates sufficient to advance to a full research program. The partner's identity has not been disclosed.
Under the agreement, the biopharma partner provides an upfront payment and fully funds XtalPi's early R&D efforts. XtalPi is eligible to receive preclinical, clinical, and commercial milestone payments plus future royalties, bringing total potential deal value to over USD 400 million. Individual milestone amounts and royalty rates were not disclosed.
Deal context
The GPCR target at the center of this XtalPi biopharma partnership is described as exhibiting extreme conformational plasticity, with no publicly reported high-resolution experimental structures bound to small-molecule ligands. That structural data void has historically limited conventional high-throughput screening approaches, which struggle to deliver candidates meeting simultaneous requirements for potency, subtype selectivity, and oral bioavailability against highly dynamic receptors.
XtalPi deployed multiscale enhanced sampling simulations to map the receptor's conformational landscape, combined with its proprietary XFEP (Free Energy Perturbation) platform for binding affinity prediction. The company then applied generative AI and a closed-loop Design-Make-Test-Analyze (DMTA) system — integrating automated robotic synthesis with quantum physics-based computational modeling — to prosecute candidates against the target. The specific GPCR identity and metabolic indication have not been disclosed.